



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 4776

## Inhibition of a multiproduct terpene synthase from *Medicago truncatula* by 3-bromoprenyl diphosphates†

Abith Vattekkatte,<sup>a</sup> Nathalie Gatto,<sup>a</sup> Eva Schulze,<sup>b</sup> Wolfgang Brandt<sup>b</sup> and Wilhelm Boland<sup>\*a</sup>

The multiproduct sesquiterpene synthase MtTPS5 from *Medicago truncatula* catalyzes the conversion of farnesyl diphosphate (FDP) into a complex mixture of 27 terpenoids. 3-Bromo substrate analogues of geranyl diphosphate (3-BrGDP) and farnesyl diphosphate (3-BrFDP) were evaluated as substrates of MTPS5 enzyme. Kinetic studies demonstrated that these compounds were highly potent competitive inhibitors of the MtTPS5 enzyme with fast binding and slow reversibility. Since there is a lack of knowledge about the crystal structure of multiproduct terpene synthases, these molecules might be ideal candidates for obtaining a co-crystal structure with multiproduct terpene synthases. Due to the structural and mechanistic similarity between various terpene synthases we expect these 3-bromo isoprenoids to be ideal probes for crystal structure studies.

Received 13th March 2015,  
Accepted 18th March 2015

DOI: 10.1039/c5ob00506j

www.rsc.org/obc

Terpenes constitute the largest and most diverse class of plant natural products with more than 55 000 members.<sup>1</sup> They serve many biological functions such as hormones, structural components of membranes, attractants for pollinators, toxins, feeding or as oviposition deterrents to insects.<sup>2–5</sup> Despite their enormous structural variety, all terpenes are essentially derived from simple linear precursors such as geranyl diphosphate (GDP), farnesyl diphosphate (FDP), and geranylgeranyl diphosphate (GGDP). The cyclization of GDP to monoterpenes, FDP to sesquiterpenes and GGDP to diterpenes is accomplished by enzymes known as terpene synthases. Structurally, sesquiterpenes are one of the most diverse classes of terpenes isolated from plants, fungi, bacteria, and marine invertebrates.<sup>6</sup> All sesquiterpenoids known to date are based on 300 basic hydrocarbon skeletons; these skeletons are generated by cyclization of FDP by sesquiterpene synthases.<sup>7</sup>

Sesquiterpene synthases are capable of catalyzing the formation of some of the most complex carbon–carbon bond forming reactions found in nature.<sup>8</sup> Despite of their promiscuous nature, active site of these synthases strictly control the reaction pathway by directing the way isoprenoid chain folds, shielding the cation from early nucleophilic attack, and guiding carbocation cascade to its final products by quench-

ing. Even in sesquiterpene synthases, while some generate a single product, others produce complex bouquets of acyclic and cyclic products from a single precursor.<sup>9</sup> The  $\delta$ -selinene synthase and the  $\gamma$ -humulene synthase from *Abies grandis* hold the current record for producing 52 and 34 different sesquiterpenes, respectively.<sup>10</sup> The lack of crystal structures of multiproduct terpene synthases, has led to great interest in the three-dimensional contour of the active site which retains such control over the reaction cascade. This knowledge is pivotal as it forms the mechanistic basis for the varying selectivity resulting in different conformations of the reactive cationic intermediates. Earlier we had reported that a multiproduct terpene synthase MtTPS5 (Fig. 1) from *Medicago truncatula* produces 27 products from FDP.<sup>11,12</sup>





Fig. 1 GC chromatogram of sesquiterpenoids formed on incubation of FDP with MtTPS5 from *M. truncatula*.

<sup>a</sup>Department of Bioorganic Chemistry, Max Planck Institute for Chemical Ecology, Hans-Knöll-Strasse 8, D-07745 Jena, Germany. E-mail: boland@ice.mpg.de

<sup>b</sup>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, Weinberg 3, 06120 Halle (Saale), Germany

† Electronic supplementary information (ESI) available: Experimental procedure and spectra are included. See DOI: 10.1039/c5ob00506j






**Scheme 1** Simplified cyclization pathways of FDP with MtTPS5.

We had also previously proposed the complex mechanistic pathway controlled by the MtTPS5 using a combination of techniques including labelling experiments.<sup>11</sup> In brief, the reaction cascade is initiated by the formation of a highly reactive farnesyl carbocation by the disassociation of diphosphate moiety. The C1 to C11 ring closure affords the humulyl cation, which generates terpenoids such as  $\alpha$ -humulene and  $\beta$ -caryophyllene (Scheme 1). Most of the products require the initial C1 to C10 closure generating the germacren-11-yl cation which is further cyclized to products like germacrene D and germacrenyl based alcohols. The other key cationic intermediates are (2Z,6E)-germacren-1-yl cation and cadinan-7-yl cation, leading to about 80% of products. These intermediates are generated by isomerization of FDP to nerolidyl diphosphate (NDP). Even alteration of a single amino acid has a dramatic effect on the product profile; alteration of tyrosine to phenylalanine in MtTPS5 prevents the formation of a key intermediate *via* protonation of germacrene D. The tight control of the enzyme leads to optically pure products resulting from cyclization steps and hydride shifts. Hence, it is of vital importance to understand the electrostatic interactions within active site. One possibility is to link the structure with complex catalytic cascade by using alternate substrates.<sup>13</sup>

Substrate analogues have been used successfully to probe the specificity of the enzymes and obtain a substrate-bound crystal structure of enzymes.<sup>14–16</sup> Natural biosynthesis allows these substrates to carry only methyl substituents, but synthetic approaches can provide various analogues of the natural substrates. Especially, substitution with sulphur has been used quite successfully for co-crystallization with different terpene synthases.<sup>17,18</sup> In a recent example from Heaps *et al.*,<sup>14</sup> chlori-



**Fig. 2** GDP analogue (3-BrGDP) and FDP analogue (3-BrFDP).

nated substrates have been shown to be alternative co-substrates for farnesyl diphosphate synthase and also acting as inhibitors when both substrates were chlorinated. Fluorinated substrates have been successfully used to study the cyclization mechanism of several terpene synthases, in particular the aristolochene synthases.<sup>19</sup> Thus, non-natural substrates have shown great potential as substrates or inhibitors to probe mechanisms and can be further utilized for the investigation of multiproduct terpene synthases.


Based on the information obtained from mechanistic studies of MtTPS5,<sup>11</sup> we have designed a set of functional analogues of prenyl diphosphates for this enzyme that could destabilize the developing allylic carbocation. The GDP analogue (3-BrGDP) and FDP analogue (3-BrFDP) (Fig. 2) were considered because of their geometrical similarity and virtually identical van der Waals radius and volume (*ca.* 2.0 Å,<sup>20</sup> *cf.* also Fig. 6) with the methyl group at C3 position of natural substrates. The highly electronegative bromine atom can strongly influence the stability of the neighboring carbocationic species but imposes no additional steric effect in comparison with the corresponding natural substrates. These analogues could either provide novel sesquiterpenes that could be further utilized to investigate mechanistic aspects of the MtTPS5, or they could act as potent inhibitors of MtTPS5. In case of inhibition it can be used to provide an active site resolved crystal structure like in the case of aristolochene synthase with farnesyl-S-thiolodiphosphate.<sup>21</sup> There is a lack of definitive understanding about the structure of multiproduct terpene synthases due to the absence of their crystal structures. These easy to synthesize inhibitors with identical sterical features could prove to be valuable tool for understanding the complex cyclization sequences in the active sites of these terpene cyclases.

## Results and discussion

### Synthesis

In order to investigate the potential of modified prenyl diphosphates, we have synthesized 3-bromo analogs of GDP (3-BrGDP) and FDP (3-BrFDP) as shown in Scheme 2. Alkylation of the THP ether of propargyl alcohol with 1-bromo-3-methylbut-2-ene (**1a**) and (*E*)-1-bromo-3,7-dimethylocta-2,6-diene (**1b**) provided the alkynes (**2a,b**) that were deprotected (MeOH, PPTS) to the propargyl alcohols (**3a**) and (**3b**). Reduction of the alcohols (**3a**) and (**3b**) with Red-Al, followed by reaction with *N*-bromosuccinimide gave the 3-bromo (*E*)-allylic alcohols (**4a**) and (**4b**). These alcohols were converted to 3-BrGDP (**5a**) and 3-BrFDP (**5b**) by sequential treatment with





**Scheme 2** Synthesis of 3-BrGDP (**5a**) and 3-BrFDP (**5b**).


*N*-chlorosuccinimide and tris-(tetrabutyl-ammonium) hydrogen pyrophosphate in acetonitrile to yield the corresponding 3-bromoprenyl diphosphates.

### Enzymatic characterizations of substrates

**Inhibition studies.** To test whether MtTPS5 would accommodate the replacement of a methyl group with a bromine atom, the terpene synthase from *Medicago truncatula* was incubated with the brominated analogues 3-BrGDP (**5a**) and 3-BrFDP (**5b**). Standard assays contained purified protein in assay buffer with substrate. The reaction mixture was covered with pentane containing dodecane as an internal standard to allow the quantification of reaction products. After being incubated for 90 min at 30 °C, the reaction was stopped and frozen in liquid nitrogen, and the pentane layer removed. The terpeneoid profiles resulting from the incubation experiments were analyzed by gas chromatography and compared to the profiles resulting from (2*E*)-GDP and (2*E*,6*E*)-FDP with the same enzyme. Results obtained by incubating both 3-BrGDP (**5a**) and 3-BrFDP (**5b**) with MtTPS5 showed no detectable formation of products. Longer incubation times (up to 24 hours) along with increased substrate and enzyme concentrations neither gave detectable amounts of brominated products or any other terpene-based derivatives. This indicated that enzyme is not able to initiate its catalytic cascade using 3-bromo substrates.

Both 3-BrGDP (**5a**) and 3-BrFDP (**5b**) were then assayed as inhibitors of the MtTPS5. With immediate mixing of enzyme, substrate, and inhibitor (no preincubation of enzyme and inhibitor), 3-BrGDP (**5a**) and 3-BrFDP (**5b**) were found to inhibit the MtTPS5 (Fig. 3). After preincubation for 1 h, standard assays containing protein in assay buffer with inhibitor and with natural substrate were performed (Fig. 3). The  $K_i$ , which was measured against MtTPS5 with 3-BrFDP (**5b**), was determined to be  $1.54 \pm 0.21 \mu\text{M}$  and  $K_i$  with BrGDP (**5a**) was determined to be  $1.25 \pm 0.23 \mu\text{M}$ . Additional preincubations with the enzyme for 1, 2, 4 and 12 h prior to substrate addition at  $t = 0$ , showed no increase in potency of inhibition, demonstrating a fast onset of the inhibition of the enzyme.

**Reversibility of inhibition.** To determine whether the mechanism of inhibition of MtTPS5 by these compounds is rapidly reversible, slowly reversible, or irreversible, the activity was evaluated using a preincubation/dilution assay.<sup>22</sup> To test the reversibility of the inhibition with 3-BrFDP (**5b**), MtTPS5 at



**Fig. 3** Double reciprocal plots of initial rates versus the concentration of substrate for MtTPS5 catalyzed turnover of FDP in the presence of 3-BrGDP (**5a**) and 3-BrFDP (**5b**) are shown on panels A and B respectively.






Fig. 4 Reversibility of Inhibition of MtTPS5 by 3-BrFDP (5b).

100-fold (its final assay concentration), and inhibitor at 10-fold its calculated  $IC_{50}$ , a condition is created where >90% of the enzyme should be in an enzyme-inhibitor complex. Upon 100-fold dilution of the enzyme pre-incubated mixture of enzyme-inhibitor complex and addition to assay buffer with substrate FDP, product formation was inhibited immediately after the addition of substrate because almost all the inhibitor 3-BrFDP (5b) was bound to the enzyme. Following the preincubated enzyme-inhibitor reaction condition for activity in separate assays, approximately 11% of the enzymatic activity in the inhibited reaction was returned after 50 minutes (Fig. 4). After 150 minutes, the rate of product formation for the pre-incubated reaction was about 5 times greater than the initial rate of product formation, showing that the inhibitor was being released from the enzyme-inhibitor complex and enzymatic activity was indeed recovering. Accordingly, 3-BrFDP (5b) acts as a very slow reversible inhibitor of the MtTPS5.

**Ab initio calculations.** This established that 3-BrGDP (5a) and 3-BrFDP (5b) inhibit the cyclization process of MtTPS5. It has already been shown that the allylic and vinyl fluoro substituents also have a retarding effect on the reactivity of various fluoro geranyl methanesulfonates.<sup>16,23</sup> The bromo substituent at C3 has a large inductive electron withdrawing effect on the electron density of the adjoining double bond which evidently decreases its  $\pi$  basicity. This effect dramatically alters the stability of the allylic carbocations during the activation of the diphosphate substrate. Thus, for all enzymes proceeding through particular type of carbocationic intermediates as shown in Fig. 5, 3-bromo analogues would be poor substrates.

To investigate the influence of the 3-bromo substitution on the destabilization of the intermediate allyl cation, reaction energies calculations were carried out using TURBOMOLE<sup>24</sup> using DFT (B3-LYP<sup>25,26</sup>) with the def-TZVPP basis set.<sup>27</sup> These calculations were performed for the corresponding cleavage of dimethylallyl diphosphate (DMAPP) and compared with 3-bromoallyl diphosphate (3-BrDMAPP) (Fig. 5). Whereas the cleavage of DMAPP requires only  $31.9 \text{ kcal mol}^{-1}$ , the corresponding 3-bromo analogue requires much more energy




Fig. 5 *Ab initio* energy calculations for cleavage of DMAPP and 3-BrDMAPP.

( $123.5 \text{ kcal mol}^{-1}$ ) and is clearly not energetically favorable. In the case of longer isoprenyl chains like GDP and FDP, the resulting carbocations are stabilized by specific cyclizations guided by the enzymatic active site. However, in case of 3-bromo analogues the huge endothermic energy required for the formation of the intermediate allyl cation prevents its formation, and hence, subsequent energy gain by cyclization is not possible. However, 3-Br GDP and 3-Br FDP are able to bind to the enzyme because there is no steric difference on comparison with the natural substrates. Since the dissociation of the diphosphate moiety is the first step, common to all prenyl diphosphate based terpenoid synthases and cyclases, we expect this simple analogues as a broadly applicable inhibitors. Preliminary experiments with a terpenoid synthase from insects isoprenyl diphosphate synthase 1 (PcIDS1)<sup>28</sup> from *Phaedon cochleariae* showed no catalytic formation of GDP with the incubation of substrates DMADP and IDP.


### Molecular mechanics simulations

In the case of the MtTPS5 enzyme, the three-dimensional contour of the active site forms the structural basis of varying selectivity that allows different conformations of the reactive cationic intermediates. Since the crystal structure for MtTPS5 is not yet known, we earlier compared the structure with the 5-*epi*-aristolochene synthase (TEAS) from *Nicotiana tabacum* that transforms FDP to 5-*epi*-aristolochene through the stable intermediate germacrene A which is also an intermediate of the MtTPS5 catalyzed reaction sequence.<sup>7</sup> Starting from the TEAS crystal structure, Starks *et al.*<sup>29</sup> suspected that the hydroxyl group of tyrosine in the interaction with the two aspartate participates as a proton donor in the activation of germacrene A and forms a catalytic triad.<sup>29</sup> A comparison of the TEAS amino acid sequence shows that all three amino acids were conserved in MtTPS5 as well. This sequence similarity can be used to our advantage to model the active site interactions leading to products.

Recently, the co-crystal structure of aristolochene synthase (PDB code: 4KUX) from *Aspergillus terreus* with a bound FSDP, a stable FDP analogue was reported. Despite differences in sequence alignment, the discussed triad the 84DDXXE motif essential for the diphosphate recognition corresponds with a







**Fig. 6** Docking arrangement of FDP (A) and 3-BrFDP (5b) (B) in the active site of the X-ray structure of aristolochene synthase (4KUX). The van der Waals radii are shown by a cloud around CH<sub>3</sub> and Br groups.

similar motif 306DDXXD in MtTPS5. Thus, there is more likely to be comparable binding of the substrate or inhibitor is more likely. This is further supported when analyzing the active site (Fig. 6) of 4KUX with bound FSDP. The influence of the bromine substitution was analyzed first by replacement of the sulfur in FSDP with oxygen to form FDP and further modifying the ligand to 3-BrFDP (5b). The active site with ligands was energy minimized within an area of 7 Å around the ligand using the YASARA package.<sup>30</sup> There were no changes in key structural features in case of interaction between the catalytic triad and C3 methyl group placed in the hydrophobic area created by F147 and partly by L80 (Fig. 4). The sequence alignment with MtTPS5 shows that both F147 and L80 are superposed with F374 and L302, respectively. Thus, almost identical hydrophobic interactions especially of the 3-Me or 3-Br moiety in MtTPS5 can be expected. The folding pattern of both substrates in the active site might be identical and the dissociation of the diphosphate moiety should lead to initiation of formation of cyclic products. To check if the bromine is able to exhibit special stabilizing interactions, distances to spatially neighboring atoms were measured. Except of the mentioned interactions with the side chains of F147 and L80

there is only one carboxyl oxygen atoms of D84 in a distance of 3.9 Å which is, however, too large for significant stabilizing interactions. This distance is larger than 3.4 Å, the sums of the respective van der Waals radii, and also the C–Br–O angle (50°) is not appropriate to lead to an ideal scenario for the formation of an attractive Br–O halogen bond.<sup>31</sup> Thus, we can conclude that natural FDP and 3-BrFDP (5b) bind to the active site in identical ways, and due to higher endothermic energy requirements the cleavage to a carbocation intermediate is not possible leading to absence of products.

## Conclusion

The 3-bromo substituted GDP (3-BrGDP) and FDP (3-BrFDP) were evaluated as substrates or inhibitors for the MTPS5 enzyme. The brominated analogues were not accepted as natural substrates for MtTPS5 and no product formation was observed. Our kinetic analyses demonstrated that these compounds were highly potent, acting as linear competitive inhibitors of the MtTPS5 enzyme, with fast binding and slow reversibility. Since there is a lack of knowledge about the crystal structure of multiproduct terpene synthases, these molecules would be ideal candidates for obtaining a co-crystal structure with e.g. the MtTPS5 from *M. truncatula*. They would not only support the co-crystallization process, but also give information on the conformation of the substrate bound in the crystal structure which is imperative in determining the precise nature of mechanism catalyzed by the enzyme. Due to the structural similarity between various terpene synthases, and similarity in behavior in active site, we expect these 3-bromo isoprenoids as ideal probes for crystal structure studies. The bromo substituent provides additional advantage to determine the absolute configuration based on the anomalous dispersion effect.<sup>32,33</sup>

## Experimental

### General methods

Reactions were performed under Ar. Solvents were dried according to standard procedures. <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR were recorded at 400 MHz. Chemical shifts of <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR are given in ppm (δ) based on solvent peaks. CDCl<sub>3</sub>: 7.27 (<sup>1</sup>H NMR) and 77.4 ppm (<sup>13</sup>C NMR). D<sub>2</sub>O/ND<sub>4</sub>OD: 4.79 (<sup>1</sup>H NMR); <sup>13</sup>C NMR and <sup>31</sup>P NMR were referenced to external standard 3-(trimethylsilyl)-propionic acid-d<sub>4</sub> sodium salt (TSP; 3% in D<sub>2</sub>O) and phosphoric acid (H<sub>3</sub>PO<sub>4</sub>, 10% in D<sub>2</sub>O), respectively. IR: Bruker Equinox 55 FTIR spectrophotometer.

### Protein expression

Strains of *E. coli* (BL21-CodonPlus(DE3)) with recombinant vectors of MtTPS5<sup>12</sup> and N-terminal His<sub>8</sub>-tag were grown to A<sub>600</sub> = 0.5 at 37 °C in LB-medium with kanamycin (50 µg ml<sup>-1</sup>). After induction with isopropyl β-D-1-thiogalactopyranoside (IPTG), cultures were shaken overnight at 16 °C. Cells were



harvested by centrifugation and the pellet was resuspended in lysis buffer (50 mM  $\text{NaH}_2\text{PO}_4$ , 300 mM NaCl, 10 mM imidazole, pH 8.0) and incubated with lysozyme. After disruption of the cells by sonication, cell debris were removed by centrifugation. The supernatant was passed over a column of  $\text{Ni}^{2+}$ -NTA-Agarose (QIAGEN, Germany), equilibrated with lysis buffer. After being washed twice with washing buffer (50 mM  $\text{NaH}_2\text{PO}_4$ , 300 mM NaCl, 20 mM imidazole), the protein was eluted with elution buffer (50 mM  $\text{NaH}_2\text{PO}_4$ , 300 mM NaCl, 250 mM imidazole). The purified protein was desalted into a TRIS-buffer (50 mM TRIS, pH 7.5, 10 mM NaCl, 10% glycerol) by passing through a NAP 25 column (Amersham Biosciences, Sweden), diluted to reach a concentration of 0.2 and 1  $\text{mg ml}^{-1}$  and stored at  $-20^\circ\text{C}$ .

### Assay for terpene synthase activity

Standard assays contained 600 nM purified protein in assay buffer (25 mM HEPES, pH 7.5, 10% glycerol, 10 mM  $\text{MgCl}_2$ , 1 mM DTT) with 50  $\mu\text{M}$  substrate in 1 mL final volume. The reaction mixture was covered with 100  $\mu\text{L}$  of pentane (1 ng  $\mu\text{L}^{-1}$  of dodecane as an internal standard) to trap the reaction products. After being incubated for 90 min at  $30^\circ\text{C}$ , the reaction was stopped by vortexing for 20 s. The whole mixture was frozen in liquid nitrogen, and the pentane layer was removed after thawing and analyzed by GC-MS.

### Gas chromatography

GC-MS analysis was performed on an instrument equipped with a ZB-5 capillary column (0.25 mm i.d.  $\times$  15 m with 0.25  $\mu\text{m}$  film). One microliter of the sample was injected in splitless mode at injection port temperature of  $220^\circ\text{C}$ . The oven temperature was kept at  $50^\circ\text{C}$  for 2 min followed by a ramp of  $10^\circ\text{C min}^{-1}$  to  $240^\circ\text{C}$  followed by an additional ramp of  $30^\circ\text{C min}^{-1}$  to  $280^\circ\text{C}$  and finally kept for 2 min. Helium at a flow rate of  $1.5 \text{ mL min}^{-1}$  served as carrier gas. Ionization potential was set to 70 eV, and scanning was performed from 40 to 250 amu. Compounds were identified by comparing their mass spectra and Kováts indices (retention indices) with published reference spectra (Garms *et al.*<sup>11</sup>) For quantification of enzyme products, the compounds were first separated on a gas chromatograph ( $\text{H}_2$  carrier gas  $1.5 \text{ mL min}^{-1}$ , injection volume 2  $\mu\text{L}$ ) under the conditions described above and subsequently analyzed on a flame ionization detector (FID) ( $250^\circ\text{C}$ ). Correction of the different response factors of sesquiterpene hydrocarbons and alcohols was achieved using calibration curves obtained from samples with different concentrations of (*E*)- $\beta$ -caryophyllene and torreyol. The average and standard deviations of relative ratios were determined by at least four independent samples setting the sum of identified compounds to 100%.

### Kinetic characterization of 3-bromo analogues as inhibitors of MtTPS5

For kinetic studies, terpene synthase activity was determined by monitoring the decrease in absorbance at 340 nm as a consequence of the consumption of NADPH coupled to the

release of pyrophosphate. Pyrophosphate was detected using a coupled-enzyme system supplied as a pyrophosphate reagent by Sigma-Aldrich. This reagent was reconstituted in buffer (16.7 mg in 1 ml 10 mM Tris-HCl, 10 mM  $\text{MgCl}_2$ , 1 mM  $\beta$ -mercaptoethanol, pH 8). Assay reaction mixtures were prepared in 96-well microplates with 50  $\mu\text{L}$  of pyrophosphate reagent, 90  $\mu\text{L}$  of buffer (0–16  $\mu\text{M}$  inhibitor, 25 mM HEPES, pH 7.5, 10% glycerol, 10 mM  $\text{MgCl}_2$ , 1 mM DTT) and 10  $\mu\text{L}$  of various concentrations of FPP. Similarly, a blank reaction mixture without FPP (instead, 10  $\mu\text{L}$  of buffer was used) was prepared, and both reaction mixtures were preheated at  $30^\circ\text{C}$  for 5 min. Next, 5  $\mu\text{L}$  of enzyme (0.2  $\text{mg ml}^{-1}$ ) was added to both mixtures to start the reactions. The activity was determined as the difference between the decrease in absorbance per minute of the sample and of the blank.

Apart from spectrophotometry based measurements, Assays (1 ml final volume) were initiated by addition of purified MTTPS5 solution (600 nM). Assays contained 0.1–5  $\mu\text{M}$  farnesyl diphosphate, 0–3  $\mu\text{M}$  inhibitor, 25 mM HEPES, pH 7.5, 10% glycerol, 10 mM  $\text{MgCl}_2$ , 1 mM DTT and were warmed to  $30^\circ\text{C}$  prior to addition of enzyme solution. After incubation for 90 min, each assay was stopped by addition of 100 mM EDTA and 100  $\mu\text{L}$  of pentane containing 1 ng  $\mu\text{L}^{-1}$  of dodecane as an internal standard to trap the reaction products. After vortexing for 10 s, the pooled hexane extracts were vortexed with silica (50 mg) the sample was centrifuged at 13 000 rpm for 5 min and then the hexane was decanted into a vial and the activity quantified.  $K_M$  and  $K_{M(\text{app})}$  values were determined by a nonlinear fit of the data to the equation  $V = V_{\text{max}}[S]/(K_M + [S])$  using Origin 8G. Mode of action of the inhibitors was determined by examination of double reciprocal plots of  $1/v$  versus  $1/[S]$ .  $K_i$  values were determined using plots of  $[I]$  versus  $K_{M(\text{app})}$  once each inhibitor was observed to be competitive.

### Modelling studies

**Ab initio calculations.** To investigate the influence of the 3-Br methyl substitution on the (de)stabilization of the immediately formed allyl cation energy optimizations were carried out with TURBOMOLE<sup>24</sup> using DFT (B3-LYP<sup>25,26</sup>) with the def-TZVPP basis set<sup>27</sup> for the cleavage of dimethyl allyl diphosphate in comparison to 3-bromo methyl allyl diphosphate as model compounds.

**Molecular mechanics simulations.** The binding mode of FPP was further analyzed using an aristolochene synthase from *Aspergillus terreus*. A full crystal structure with bound FPP analogue is available of this enzyme (4UKX).<sup>21</sup> Both enzymes, MtTPS5 and the aristolochene synthase, bind FPP and most likely also 3Br-FPP. The influence of the bromine substitution was analyzed by modifying the ligand and comparing the binding after energy minimization. Therefore, the crystal structure was used, hydrogens were added and the FPP analogue was changed to FPP (*i.e.* the sulfur atom at the diphosphate moiety was changed to oxygen) and the area of 7 Å around the ligand was minimized using the yasara 2 force field of the YASARA package.<sup>30</sup> The binding of the 3Br-FPP was similarly modelled. The methyl group at position 3 of the FPP was con-



verted into bromine and 7 Å around the ligand was minimized using the yasara 2 force field. The comparison of the two binding modes revealed FPP and 3Br-FPP could be bound similar by the enzyme.

### Synthetic procedure

**2-((7-Methyloct-6-en-2-yn-1-yl)oxy)tetrahydro-2H-pyran (2a).**<sup>34</sup> The alkyne (2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran) (2.00 g, 14.3 mmol) was dissolved in dry DMI (20 ml). The solution was cooled to 0 °C, and *n*-butyllithium (1.39 M in hexanes, 10.3 ml, 14.3 mmol) was added by syringe over 15 min. Then stirred for 30 min, and further the 5-bromo-2-methylpent-2-ene **1a** (2.00 g, 9.52 mmol) in dry DMI (10 ml) was added. The reaction was warmed to room temperature and stirred for 5 h. Sat. aq. NaCl (50 ml) was added and the solution was extracted with petroleum ether (3 × 50 ml). The combined organic phase was dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to give yellow oil which was heated to 70 °C under vacuum to distill off most of the excess alkyne. The remaining oil was chromatographed on silica gel (9 : 1 hexanes–diethyl ether) to give 1.264 g of **2a** (63%) as a colorless oil data: (lit.<sup>34</sup>) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.12–5.14 (1H, m), 4.79 (1H, t, *J* = 3.3 Hz), 4.22 (2H, app q), 3.79–3.85 (1H, m), 3.49–3.53 (1H, m), 2.17–2.21 (4H, m), 1.68 (3H, s), 1.60 (3H, s), 1.50–1.91 (6H, m); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 132.9, 122.8, 96.5, 86.4, 75.7, 61.9, 54.5, 30.2, 27.3, 24.6, 25.3, 19.3, 19.1, 17.7. IR (neat) cm<sup>−1</sup>: ν 2942, 2870, 1441, 1117, 1024.

**(2E)-2-((7,11-Dimethyldodeca-6,10-dien-2-yn-1-yl)oxy)tetrahydro-2H-pyran (2b).** First step in synthesis (2E)-2-((7,11-dimethyldodeca-6,10-dien-2-yn-1-yl)oxy)tetrahydro-2H-pyran (**2b**) was the conversion of homogeraniol to (2E)-9-bromo-2,6-dimethylnona-2,6-diene (**1b**) by following procedure of Oehlschlager *et al.*<sup>35</sup>

**(2E)-9-Bromo-2,6-dimethylnona-2,6-diene (1b).**<sup>35</sup> To an ice-cooled solution of triphenylphosphine (1.5 g, 5.5 mmol) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub>, bromine was added dropwise until a permanent yellow color appeared. A few milligrams of triphenylphosphine were added to consume excess Br<sub>2</sub> and then pyridine (0.8 mL, 10 mmol) was added and stirred for 10 min. Homogeraniol (0.85 g, 5 mmol) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> was added dropwise and the reaction was stirred for further 90 min. The sample was concentrated and remainder precipitate was washed with pentane (4 × 50 mL), and the combined pentane extracts were washed with 1 N HCl (25 mL) and brine (2 × 30 mL), dried with MgSO<sub>4</sub>, filtered and concentrated *in vacuo*. Distillation gave (2E)-2-((7,11-dimethyldodeca-6,10-dien-2-yn-1-yl)oxy)tetrahydro-2H-pyran (**2b**) (0.80 g, 71%); bp 90–92 °C <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.03–5.27 (m, 2H), 3.27–3.52 (t, 2H, C<sub>1</sub>–CH<sub>2</sub>, *J* = 6.66 Hz), 2.39–2.74 (q, 2H, C<sub>2</sub>–CH<sub>2</sub>, *J* = 6.67 Hz), 1.96–2.13 (m, 4H), 1.69 (s, 3H) 1.62 (s, 6H); MS, *m/z* (rel. intensity), 232 (10.5), 230 (11.7), 217 (5.8), 215 (8.2), 189 (28.2), 187 (30.5), 123 (18.8), 69 (100).

**(2E)-2-((7,11-Dimethyldodeca-6,10-dien-2-yn-1-yl)oxy)tetrahydro-2H-pyran (2b).** The alkyne (2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran) (2.00 g, 14.3 mmol) was dissolved in dry DMI (20 ml). The solution was cooled to 0 °C, and *n*-butyllithium (1.39 M in

hexanes, 10.3 ml, 14.3 mmol) was added slowly by syringe over 15 min. The reaction was stirred for 30 min, and then (2E)-9-bromo-2,6-dimethylnona-2,6-diene (**1b**) (2.76 g, 9.52 mmol) in dry DMI (10 ml) was added. The reaction was warmed to room temperature and stirred for 5 h. Sat. aq. NaCl (50 ml) was added and the solution was extracted with petroleum ether (3 × 50 ml). The combined organic phase was dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to give yellow oil which was heated to 70 °C under vacuum to distill off most of the excess alkyne. The remaining oil was chromatographed on silica gel (9 : 1 hexanes–diethyl ether) to give 1.051 g of **2a** (51%) as a colorless oil data: (lit.<sup>36</sup>) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.18 (s, 1H), 5.07 (s, 1H), 4.76 (s, 1H), 4.2 (t, *J* = 2 Hz, 2H), 3.6 (m, 2H), 2.9 (d, *J* = 7 Hz, 2H), 1.98 (m, 4H), 1.62 (m, 1H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 135.9, 132.6, 122.8, 123.5, 100.2, 87.8, 75.7, 63.3, 54.5, 39.7, 30.2, 27.3, 25.9, 25.4, 24.6, 20.8, 19.3, 18.9, 17.3. IR (neat) cm<sup>−1</sup>: ν 3060, 2960, 2240, 1140.

**7-Methyloct-6-en-2-yn-1-ol (3a).** The alkyne THP ether 2-((7-methyloct-6-en-2-yn-1-yl)oxy)tetrahydro-2H-pyran (**2a**) (1.667 g, 7.50 mmol) was dissolved in methanol (100 ml). Hydrochloric acid (concentrated, 5 drops, catalytic amount) was added. The reaction was stirred at room temperature for 1 h. The reaction was poured into a separatory funnel containing sat. aq. NaHCO<sub>3</sub> (15 ml) and extracted with dichloromethane (3 × 50 ml). The combined organic phase was dried (MgSO<sub>4</sub>), concentrated *in vacuo*, and chromatographed on silica gel (1 : 1 hexanes–diethyl ether) to give 0.828 g of the alcohol **4a** (80%) as a colorless oil. (bp: 93–5 °C) as a colorless oil. *R*<sub>f</sub> 0.43 (1 : 1 hexanes–ether); data: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.18–5.13 (m, 1H), 4.25 (s, 2H), 2.26–2.17 (m, 4H), 1.70 (s, 3H), 1.62 (s, 3H), 1.52 (s, 1H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 133.1, 122.6, 86.4, 78.3, 51.4, 27.3, 25.6, 19.2, 17.7; HRMS calcd for C<sub>9</sub>H<sub>14</sub>O 138.1045, found 138.1041. IR (neat) cm<sup>−1</sup>: ν 3550–3160, 2970, 2920, 2860, 2280, 2220, 1470, 1370, 1130, 1100, 1010 cm<sup>−1</sup>.

**(2E)-7,11-Dimethyldodeca-6,10-dien-2-yn-1-ol (3b).** The alkyne THP ether (2E)-2-((7,11-dimethyldodeca-6,10-dien-2-yn-1-yl)oxy)tetrahydro-2H-pyran (**2b**) (2.175 g, 7.50 mmol) was dissolved in methanol (100 ml). Hydrochloric acid (concentrated, 5 drops, catalytic amount) was added. The reaction was stirred at room temperature for 1 h. The reaction was poured into a separatory funnel containing sat. aq. NaHCO<sub>3</sub> (15 ml) and extracted with dichloromethane (3 × 50 ml). The combined organic phase was dried (MgSO<sub>4</sub>), concentrated *in vacuo*, and chromatographed on silica gel (1 : 1 hexanes–diethyl ether) to give 1.282 g of the alcohol **4a** (83%) as a colorless oil. (bp 120–124 °C (0.5 mm)) as a colorless oil. *R*<sub>f</sub> 0.40 (1 : 1 hexanes–ether); data: (lit.<sup>37</sup>) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.16 (m, 1H), 5.09 (m, 1H), 4.25 (d, 2H, *J* = 10.8), 2.22 (narrow m, 4H), 2.07 (m, 2H), 1.99 (m, 2H), 1.68 (s, 3H), 1.61 (s, 3H), 1.60 (s, 3H), 1.50 (t, 1H, *J* = 10.8), <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 133.1, 122.6, 86.4, 78.3, 51.4, 27.3, 25.6, 19.2, 17.7; HRMS calcd for C<sub>14</sub>H<sub>22</sub>O: 206.1671, found 206.1667 IR (neat) cm<sup>−1</sup> 3334, 2287, 2224, 1670, 1020 cm<sup>−1</sup>.

**(2E)-3-Bromo-7-methylocta-2,6-dien-1-ol (4a).** 7-Methyloct-6-en-2-yn-1-ol (**3a**) (0.317 g, 2.3 mmol) in 10 mL of dry THF was





added to a dry flask under N<sub>2</sub>. Red-Al (1.17 mL, 3.9 mmol) was added dropwise *via* syringe and the reaction mixture was allowed to stir at rt for 36 h. The reaction mixture was cooled to −78 °C and *N*-bromosuccinimide (NBS) (0.783 g, 4.4 mmol) dissolved in THF was added dropwise and the reaction mixture was allowed to stir at −78 °C for an additional 1 h. The crude mixture was stirred at 0 °C for 2 h and was quenched by the addition of saturated sodium potassium tartrate (Rochelle's salt). The aqueous layer was extracted several times with ether. The organic layers were combined, washed with brine, dried over MgSO<sub>4</sub> and concentrated. This colorless oil consisted of desired (**4a**) as an isomeric mixture (GC). The residue was purified by chromatography on silica using 1 : 1 (v/v) hexane–ether to yield 200 mg (42%) of a colorless oil (GC: 96% pure). *R*<sub>f</sub> = 0.43 (1 : 1 hexanes–ether); data: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.93 (tt, 1H), 5.08 (t, 1H), 4.26 (d, 2H), 2.50 (t, 2H), 2.25 (dt, 2H), 1.78 (s, 1H), 1.70 (s, 3H), 1.64 (s, 3H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 133.44, 130.2, 128.0, 122.5, 62.8, 42.0, 27.1, 26.0, 18.1. HRMS calcd for C<sub>14</sub>H<sub>22</sub>BrO (M – H<sub>2</sub>O) 200.0195, found 200.0196. IR (neat) cm<sup>−1</sup>: ν 3540–3100, 2970, 2930, 2850, 1705, 1635, 1445, 1375, 1080, 1020, 825.

**(2*E*,6*E*)-3-Bromo-7,11-dimethyldodeca-2,6,10-trien-1-ol (4b).** (2*E*)-7,11-Dimethyldodeca-6,10-dien-2-yn-1-ol (**3b**) (0.473 g, 2.3 mmol) in 10 mL of dry THF was added to a dry flask under N<sub>2</sub>. Red-Al (1.17 mL, 3.9 mmol) was added dropwise *via* syringe and the reaction mixture was allowed to stir at rt for 48 h. The reaction mixture was cooled to −78 °C and *N*-bromosuccinimide (NBS) (0.783 g, 4.4 mmol) dissolved in THF was added dropwise and the reaction mixture was allowed to stir at −78 °C for an additional 1 h. The crude mixture was stirred at 0 °C for 2 h and was quenched by the addition of saturated sodium potassium tartrate (Rochelle's salt). The aqueous layer was extracted several times with ether. The organic layers were combined, washed with brine, dried over MgSO<sub>4</sub> and concentrated. This colorless oil consisted of desired (**4b**) as an isomeric mixture (GC). The residue was purified by chromatography on silica using 1 : 1 (v/v) hexane–ether to yield 257 mg (39%) of a colorless oil (GC: 96% pure). *R*<sub>f</sub> = 0.40 (1 : 1 hexanes–ether); Data: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.83 (t, *J* = 5.8 Hz, 1H) 5.08 (t, *J* = 5.7 Hz, 2H), 4.18 (d, *J* = 5.8 Hz, 2H), 2.52 (m, 2H), 2.21 (m, 2H), 2.06–1.95 (m, 4H), 1.73 (s, 1H), 1.68 (s, 3H), 1.62 (s, 3H), 1.59 (s, 3H) <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ: 136.9, 133.8, 131.6, 124.4, 122.1, 110.3, 67.5, 45.6, 39.8, 28.1, 26.9, 25.9, 17.9, 16.4; HRMS calcd for C<sub>14</sub>H<sub>22</sub>BrO (M – H<sub>2</sub>O) 268.0821, found 268.0820. IR (neat) cm<sup>−1</sup>: ν 3540–3100, 2970, 2930, 2850, 1705, 1635, 1445, 1375, 1080, 1020, 825.

### General procedure for the preparation of trisammonium diphosphates

Trisammonium diphosphates were prepared according to the modified method of Woodside *et al.*<sup>38</sup> To a solution of *N*-chlorosuccinimide (11.39 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (45 mL) at −30 °C under argon was added dropwise freshly distilled dimethyl sulfide (1.1 eq. mol). The mixture was warmed to 0 °C, stirred at this temperature for 10 min and cooled to −40 °C. A solution of

alcohol **4a** or **4b** (1 eq. mol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was slowly added before the reaction mixture was warmed to 0 °C. Stirring was continued for 2 h at 0 °C and 15 min at rt. The clear solution was then washed with cold saturated NaCl (25 mL). The aqueous phase was extracted with pentane (2 × 20 mL). The combined organic layers were washed with cold saturated NaCl (20 mL), dried (MgSO<sub>4</sub>), concentrated under reduced pressure (no water bath) and completely removed under high vacuum for 2 h. Corresponding alkyl chlorides were used without further purification. Freshly prepared tris(tetrabutylammonium) hydrogen pyrophosphate (1.2 eq. mol) was dissolved in ACN (5 mL) at rt under argon before dropwise addition of alkyl chloride in ACN (2 mL). Stirring was continued at rt overnight. The mixture was concentrated under reduced pressure. The residue was dissolved in (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub> (3 mL) (0.25 mM, 2% isopropyl alcohol), loaded onto a 2 × 30 cm column of Dowex 50WX8-200 (NH<sub>4</sub><sup>+</sup> form) before elution of two volumes column of (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub> (0.25 mM, 2% isopropyl alcohol). The eluent was lyophilized and the resulting white powder was purified by chromatography on cellulose (1 : 9 (v/v) water in ACN). Fractions were monitored by TLC (silica gel, iPr-OH–water–AcOEt 6 : 3 : 1) and those containing trisammonium diphosphate were combined. Solvents were removed under reduced pressure and the resulting solution was lyophilized to afford **5a** or **5b**.

**Trisammonium (2*E*)-1-(3-bromo-7-methylocta-2,6-dienyl)-diphosphate (5a).** According the general procedure, phosphorylation of **4a** (0.127 g) gave **5a** (0.153 g, 35% from **5a**) as a flocculent white solid. mp: 157–160 °C. Data: <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: 5.94 (t, 1H, *J* = 5.8 Hz), 5.07–5.07 (m, 1H), 4.39 (t, 2H, *J* = 6.4 Hz), 2.38–2.41 (m, 2H), 2.14–2.18 (m, 2H), 1.54 (s, 3H), 1.48 (s, 3H); <sup>13</sup>C NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: 135.0, 130.6, 126.2, 122.8 (d, *J* = 7.3 Hz), 65.7 (d, *J* = 3.1 Hz), 41.4, 26.4, 25.2, 17.7; <sup>31</sup>P NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: −5.81, −10.54; HRMS (ESIMS) calcd for C<sub>9</sub>H<sub>17</sub>BrO<sub>7</sub>NaP<sub>2</sub> [M + Na]<sup>+</sup> 400.9525, found 400.9525. IR (neat) cm<sup>−1</sup>: ν 3150–2920 (br), 2320, 2197, 1649, 1447, 1207, 1092, 920.

**Trisammonium ((2*E*,6*E*)-3-bromo-7,11-dimethyldodeca-2,6,10-trienyl)diphosphate (5b).** According the general procedure, phosphorylation of **4b** (0.141 g) gave **5b** (0.131 g, 40% from **4b**) as a flocculent white solid. mp: 155–160 °C. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: 5.17–5.22 (m, 2H), 4.59 (t, 2H, *J* = 6.5 Hz), 2.40–2.44 (m, 2H), 2.27–2.31 (m, 2H), 2.09–2.14 (m, 2H), 2.02–2.04 (m, 2H), 1.69 (s, 3H), 1.63 (s, 3H), 1.62 (s, 3H); <sup>13</sup>C NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: 138.3, 138.2, 134.2, 125.1, 123.5, 123.0 (d, *J* = 7.7 Hz), 63.4 (d, *J* = 4.5 Hz), 39.4, 39.3, 26.5, 26.0, 25.5, 16.0; <sup>31</sup>P NMR (400 MHz, D<sub>2</sub>O/ND<sub>4</sub>OD) δ: −5.43, −10.51 HRMS (ESIMS) calcd for C<sub>14</sub>H<sub>25</sub>BrO<sub>7</sub>P<sub>2</sub> [M + Na]<sup>+</sup> 469.0151, found 469.0151. IR (neat) cm<sup>−1</sup>: ν 3150–2920 (br), 2320, 2197, 1649, 1447, 1207, 1092, 920.

**Trisammonium (*E*)-geranyl and (2*E*,6*E*)-farnesyl diphosphates.** Unlabeled GDP and FDP were synthesized from commercial geranyl and farnesyl chloride (Aldrich) respectively, according the phosphorylation procedure described above.





## Acknowledgements

We would like to acknowledge Max Planck Society for funding. We would also like to acknowledge Stefan Garms and Stephan von Reuss for helpful discussions. We also like to thank Peter Rahfeld and Rita Buchler for their help with protein purification.

## Notes and references

- H. V. Thulasiram, H. K. Erickson and C. D. Poulter, *Science*, 2007, **316**, 73–76.
- J. H. Langenheim, *J. Chem. Ecol.*, 1994, **20**, 1223–1280.
- E. Pichersky and J. Gershenzon, *Curr. Opin. Plant Biol.*, 2002, **5**, 237–243.
- E. Nambara and A. Marion-Poll, *Annu. Rev. Plant Biol.*, 2005, **56**, 165–185.
- M. Hilker, C. Kobs, M. Varama and K. Schrank, *J. Exp. Biol.*, 2002, **205**, 455–461.
- J. D. Connolly and R. A. Hill, *Dictionary of Terpenoids*, Chapman & Hall, New York, 1992.
- C. A. Lesburg, J. M. Caruthers, C. M. Paschall and D. W. Christianson, *Curr. Opin. Struct. Biol.*, 1998, **8**, 695.
- E. M. Davis and R. Croteau, in *Biosynthesis: Aromatic Polyketides, Isoprenoids, Alkaloids*, Springer-Verlag, Berlin, 2000, vol. 209, pp. 53–95.
- J. P. Jones, K. R. Korzekwa, A. E. Rettie and W. F. Trager, *J. Am. Chem. Soc.*, 1986, **108**, 7074.
- C. L. Steele, J. Crock, J. Bohlmann and R. Croteau, *J. Biol. Chem.*, 1998, **273**, 2078.
- S. Garms, T. G. Köllner and W. Boland, *J. Org. Chem.*, 2010, **75**, 5590–5600.
- G. I. Arimura, S. Garms, M. Maffei, S. Bossi, B. Schulze, M. Leitner, A. Mithöfer and W. Boland, *Planta*, 2008, **227**, 453–464.
- D. W. Christianson, *Chem. Rev.*, 2006, **106**, 3412–3442.
- N. A. Heaps and C. D. Poulter, *J. Org. Chem.*, 2011, **76**, 1838–1843.
- F. Y. David, J. Miller, D. W. Knight and R. K. Allemann, *Org. Biomol. Chem.*, 2009, **7**, 962–975.
- D. J. Hosfield, Y. Zhang, D. R. Dougan, A. Broun, L. W. Tari, R. V. Swanson and J. Finn, *J. Biol. Chem.*, 2004, **279**, 8526–8529.
- F.-Y. Lin, C.-I. Liu, Y.-L. Liu, Y. Zhang, K. Wang, W.-Y. Jeng, T.-P. Ko, R. Cao, A. H.-J. Wang and E. Oldfield, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 21337–21342.
- J. A. Faraldos and R. K. Allemann, *Org. Lett.*, 2011, **13**, 1202–1205.
- D. J. Miller, F. Yu, D. W. Knight and R. K. Allemann, *Org. Biomol. Chem.*, 2009, **7**, 962–975.
- A. Bondi, *J. Phys. Chem.*, 1964, **68**, 441–451.
- M. Chen, N. Al-lami, M. Janvier, E. L. D'Antonio, J. A. Faraldos, D. E. Cane, R. K. Allemann and D. W. Christianson, *Biochemistry*, 2013, **52**, 5441–5453.
- C. RA, *Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists*, John Wiley & Sons, Hoboken, NJ, 2005.
- C. D. Poulter, J. C. Argyle and E. A. Mash, *J. Biol. Chem.*, 1978, **253**, 7227–7233.
- C. Steffen, K. Thomas, U. Huniar, A. Hellweg, O. Rubner and A. Schroer, *J. Comput. Chem.*, 2010, **31**, 2967–2970.
- K. Kim and K. D. Jordan, *J. Phys. Chem.*, 1994, **98**, 10089–10094.
- P. J. Stephens, F. J. Devlin, C. F. Chabalowski and M. J. Frisch, *J. Phys. Chem.*, 1994, **98**, 11623–11627.
- F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.
- S. Frick, R. Nagel, A. Schmidt, R. R. Bodemann, P. Rahfeld, G. Pauls, W. Brandt, J. Gershenzon, W. Boland and A. Burse, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 4194–4199.
- C. M. Starks, K. W. Back, J. Chappell and J. P. Noel, *Science*, 1997, **277**, 1815.
- E. Krieger, G. Koraimann and G. Vriend, *Proteins: Struct., Funct., Bioinf.*, 2002, **47**, 393–402.
- S. Sirimulla, J. B. Bailey, R. Vegesna and M. Narayan, *J. Chem. Inf. Model.*, 2013, **53**, 2781–2791.
- Z. Dauter, M. Dauter and K. R. Rajashankar, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2000, **56**, 232–237.
- J. M. Bijvoet, A. F. Peerdeman and A. J. van Bommel, *Nature*, 1951, **168**, 271–272.
- M. E. Jung and M. H. Parker, *J. Org. Chem.*, 1997, **62**, 7094–7095.
- A. C. Oehlschlager, S. M. Singh and S. Sharma, *J. Org. Chem.*, 1991, **56**, 3856–3861.
- S. Ghosal, M. Nirmal, J. C. Medina and K. S. Kyler, *Synth. Commun.*, 1987, **17**, 1683–1694.
- J. Hooz, J. Cabezas, S. Musmanni and J. Calzada, *Org. Synth.*, 1990, **69**, 120–128.
- A. B. Woodside, H. Zheng and C. D. Poulter, *Org. Synth.*, 1988, **66**, 211–219.

